Last reviewed · How we verify
Oral Vioxx (Rofecoxib)
Rofecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain.
Rofecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain. Used for Rheumatoid arthritis, Osteoarthritis, Acute pain.
At a glance
| Generic name | Oral Vioxx (Rofecoxib) |
|---|---|
| Sponsor | Chinese University of Hong Kong |
| Drug class | COX-2 selective inhibitor (coxib) |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | Phase 3 |
Mechanism of action
As a COX-2 selective inhibitor, rofecoxib blocks the COX-2 enzyme preferentially over COX-1, thereby reducing inflammatory prostaglandins while theoretically sparing the protective prostaglandins produced by COX-1 in the gastrointestinal tract and kidneys. This selectivity was intended to provide anti-inflammatory and analgesic benefits with a lower risk of gastrointestinal ulceration compared to non-selective NSAIDs.
Approved indications
- Rheumatoid arthritis
- Osteoarthritis
- Acute pain
- Dysmenorrhea
Common side effects
- Cardiovascular thrombotic events (myocardial infarction, stroke)
- Gastrointestinal ulceration and bleeding
- Hypertension
- Edema
- Dyspepsia
Key clinical trials
- CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen (NA)
- A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee (PHASE3)
- Safety of Lumiracoxib in Patients With Osteoarthritis (PHASE3)
- Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Vioxx (Rofecoxib) CI brief — competitive landscape report
- Oral Vioxx (Rofecoxib) updates RSS · CI watch RSS
- Chinese University of Hong Kong portfolio CI